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This study tested the hypothesis that excessive tumor
necrosis factor-α (TNF-a) levels in chronic venous leg
ulcers are associated with impaired healing. TNF-a was
measured by two enzyme-linked immunosorbent assays
and a bioassay (KYM-1D4) in paired wound fluid samples
collected during the nonhealing and healing phases from
21 human patients with venous leg ulcers. Soluble TNF
receptor levels (p55 and p75) were also measured. The
levels of immunoreactive TNF-a were significantly higher
in wound fluid from nonhealing ulcers than in wound
fluid from healing ulcers (p < 0.005), whereas the levels
of bioactive TNF-a were not. Statistical analysis con-
firmed that TNF-a bioactivity relative to the amount of
immunoreactive TNF-a was downregulated in wound
fluid from nonhealing ulcers compared with healing
ulcers. The levels of soluble p55 and p75 receptors
in wound fluid showed a significant linear correlation
The factors associated with venous insufficiency thatinitiate ulceration and that impair wound healing arestill being debated. It has been established that oneeffect of venous insufficiency is impaired tissue oxygenperfusion (Mani et al, 1989; Falanga et al, 1991) that can
influence cell proliferation (Balin et al, 1984; Siddiqui et al, 1996) and
matrix deposition (Herrick et al, 1996). Others have suggested that a
key event in the pathogenesis of chronic venous ulcers is inflammation
generated by activated leukocytes trapped in the microcirculation
(Thomas et al, 1988). During normal wound healing, an initial transient
inflammatory response is an essential part of the tissue repair process.
Work in our department shows that persistent inflammation is a feature
of nonhealing venous ulcers, and that its resolution correlates with
healing. Levels of the pro-inflammatory cytokines interleukin-1,
interleukin-6, and TNF-α, and a clinical marker of inflammation, C-
reactive protein, have all been shown to decrease in wound fluid
from healing chronic venous ulcers compared with nonhealing ulcers
(Trengove et al, 1996).1
We hypothesize that prolonged inflammation impairs the healing of
chronic venous ulcers via the adverse action of cytokines that affect
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(p < 0.001), suggesting a partially coordinated or common
regulatory mechanism for the cleavage of transmembrane
TNF receptors in chronic venous ulcers in vivo. Although
the levels of soluble p75 receptors were significantly
higher in nonhealing wound fluid compared with healing
wound fluid (p < 0.025), these levels were theoretically
inadequate to substantially neutralize the bioactivity of
the accompanying TNF-a levels on their own. The
bioactivity accompanying the elevated levels of immuno-
reactive TNF-a in wound fluid from nonhealing ulcers
may have been further down-modulated by an additional
mechanism. Because healing was initiated without a
significant decline in the level of bioactive TNF-a, TNF-
a-mediated events may not be the key events contributing
to the impaired healing seen in chronic venous ulcers.
Key words: chronic wounds/inflammation. J Invest Dermatol
110:292–296, 1998
the growth or viability of cell types found in healing skin, and that
affect the integrity of the extracellular matrix. Tumor necrosis factor-
α (TNF-α) is an important proinflammatory cytokine that has been
detected in intracapillary monocytes in venous ulcer biopsies (Mirshahi
et al, 1995). TNF-α is synthesized as a 26 kDa membrane-bound
precursor and is proteolytically cleaved at the cell surface to yield the
mature secreted 17 kDa polypeptide (Jue et al, 1990) that is biologically
active as a homo-trimer (Jones et al, 1989). TNF-α can mediate
functional activation, proliferation, or apoptotic death of cells depending
on its concentration and the target cell type. The diversity of responses
induced by TNF-α may also be due to subtle complexities of post-
receptor signaling processes (Schutze et al, 1988). In vitro, TNF-α
stimulates the proliferation of dermal fibroblasts (Vilcek et al, 1986),
but inhibits cell proliferation and induces cell adhesion molecules in
keratinocytes (Detmar and Orfanos, 1990). Whereas TNF-α is a potent
functional activator of endothelial cells, it impairs their growth in vitro
(Frater-Schro¨der et al, 1987) and under certain conditions can induce
endothelial cell apoptosis (Polunovsky et al, 1994).
There are several mechanisms that may serve to regulate the
bioactivity of TNF-α in vivo. The effects of TNF-α are mediated by
two types of cell surface receptors, the p55 and p75 TNF receptors.
Both receptor subtypes may be proteolytically cleaved to produce
soluble receptor proteins, which may compete with membrane-bound
TNF receptors for TNF-α binding. There is evidence that at high
concentrations of soluble TNF receptors (sTNF-R) in vitro these
receptors can inhibit the bioactivity of TNF-α (Higuchi and Aggarwal,
1992). The functional role of sTNF-R in vivo is still being elucidated.
Reports of high levels of TNF-α, soluble p55, and soluble p75 measured
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by enzyme-linked immunosorbent assay (ELISA) in combination with
barely detectable levels of bioactive TNF-α in human plasma, have
been proposed as indirect evidence for soluble receptors reducing the
bioactivity of TNF-α in vivo (Jackson et al, 1995; Linderholm et al,
1996). In other studies, circulating soluble receptor levels in critically
ill patients and in experimental endotoxinaemia have not been sufficient
to block the accompanying TNF activity entirely (Spinas et al, 1992;
Van Zee et al, 1992). A sTNF-R fusion protein has been shown to
protect mice from lethal endotoxin challenge (Mohler et al, 1993).
Conversely, it is suggested that at low concentrations of sTNF-R, the
reversible association of the soluble receptors with TNF-α can slow
the spontaneous degradation of the labile trimeric form of the TNF-
α molecule and increase its bioavailability (Aderka et al, 1992).
The aim of this study was to examine the role of TNF-α in chronic
venous leg ulcers, and in particular to determine whether the activity
of TNF-α is likely to contribute to delayed healing. To investigate
this we tested the hypothesis that the levels of TNF-α in the extracellular
fluid collected from venous ulcers would decrease as the ulcers transform
from a nonhealing to a healing state. Bioactive levels of TNF-α were
compared with immunoreactive levels (two different ELISA) in the
nonhealing phase and after 2 wk bed rest when the ulcers showed
early clinical signs of healing. The levels of soluble p55 and p75
receptors were also determined by ELISA to establish if they have a
role in regulating the bioactivity of TNF-α in the chronic wound
environment.
MATERIALS AND METHODS
Patients Wound fluid was collected from chronic ulcers on the lower leg of
21 patients with venous disease. Patients with ulcers on the foot were excluded
from this study. The presence of venous disease was determined by clinical
history, examination, and investigations that included venous refilling time by
photoplethysmography (Abramowitz et al, 1979). Arterial Doppler pressures
were performed to assess the presence of arterial disease (Yao et al, 1968). A
diagnosis of venous disease was confirmed by a venous refilling time less than
25 s and arterial disease was determined by an ankle/brachial Doppler arterial
ratio of less than 0.9. A panel of blood tests was also performed to rule out
systemic contributing factors to ulceration, such as diabetes. In all cases the
patients’ ulcers had failed to respond to outpatient treatment (compression
therapy), showing no reduction in ulcer size over more than 3 mo or a
continued increase in ulcer size. Patients were admitted to hospital for bed rest,
six-hourly saline solution compresses, and eventual skin grafting. There were
no additional interventions with respect to other potential causes of delayed
wound healing.
Collection of wound fluid Wound fluid was collected from the patients’
ulcers within 24 h of admission to hospital (nonhealing phase) and after 2 wk
of regular saline dressings and bed rest (healing phase). Wound fluid was
collected from each patient in a standardized manner as previously described
(Trengove et al, 1996). After aspiration the fluid was transferred into Greiner
Vacuette serum collection tubes (Interpath, Melbourne, Australia). These tubes
were kept on ice for less than 1 h prior to centrifugation of the wound fluid
and storage in multiple aliquots at –80°C. Measurements of TNF-α and soluble
TNF receptor levels were performed on aliquots thawed for the first time. The
edge of each ulcer was traced onto a transparent plastic sheet and the area
determined by planimetry. The ulcer size measurements were performed on
admission to hospital and just prior to the second wound fluid collection.
TNF-a bioassay Bioactive TNF-α was assayed colorimetrically by its
cytotoxic effect on the human rhabdomyosarcoma cell line, KYM-1D4 (a kind
gift of Dr. Jay Steer, University Department of Pharmacology, University
of Western Australia), essentially as previously described (Meager, 1991).
Recombinant human TNF-α (TNF-H, Genzyme, Boston, MA) was used as
the standard for the quantitation of TNF-α in the test samples. Serial dilutions
of recombinant human TNF-α in RPMI-1640 medium (Gibco, Grand Island,
NY) plus 5% fetal calf serum (CSL, Melbourne, Australia) from 143 to 0.143 U
per ml (specific activity 1.43 3 108 U per mg) were used to construct the
standard curve. Test wound fluid samples were filter-sterilized after thawing
(0.22 µm membrane, MillexR-GV13, Millipore, MA) and diluted 15-fold in
the same medium. One hundred microliter aliquots of test and standard samples
were assayed in triplicate in 96 well tissue culture plates (Falcon, Franklin Lakes,
NJ). The KYM-1D4 cells were resuspended in culture medium at 2 3 105
cells per ml and 100 µl added to each test and standard well before incubation
of the plates at 37°C, 5% CO2. Cell survival was estimated with MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Sigma, St. Louis, MO)
Table I. Levels of immunoreactive TNF-a measured in
wound fluid from nonhealing and healing ulcers with two
different ELISA (pg per ml)
Nonhealing median Healing median Significance
(interquartile range) (interquartile range) level
Medgenix 2428.5 895.2
(1535.0–3549.2) (549.4–2523.8) p , 0.002
Genzyme 694.7 190.8 p , 0.003
(402.2–1295.0) (100–848.3)
(10 µl per well of 5 mg MTT per ml phosphate-buffered saline) (Mosmann,
1983) after 48 h. The blue formazan product of MTT conversion was eluted
with 20% sodium dodecyl sulfate (ultrapure grade, USB, Cleveland, OH) in
50% dimethylformamide pH 4.7 (Hansen et al, 1989) after 2 h at 37°C, and
the optical densities read at 570 nm.
TNF-a immunoassays Immunoreactive TNF-α in wound fluid was deter-
mined by DuoseTTM (Genzyme) and EASIATM (Medgenix, Fleurus, Belgium)
ELISA for human TNF-α. Assays were performed according to the manufac-
turer’s instructions. The same preparation of recombinant human TNF-α that
was used in the bioassay was used as the reference standard for both ELISA
(TNF-H, Genzyme). Briefly, all test samples were diluted 10-fold for each
ELISA. Standards or test samples in duplicate were incubated in microtitre
wells coated with one (Genzyme) or several (Medgenix) murine monoclonal
antibodies and detected with horseradish peroxidase-conjugated rabbit poly-
clonal antibodies. After color development of the tetramethylbenzidine substrate
the optical densities were measured at 450 nm.
Immunoassays to detect soluble TNF-receptors The levels of sTNF-R
p55 and p75 were measured in wound fluid using Biotrak ELISA (Amersham,
U.K.). Assays were performed according to the manufacturer’s instructions with
all test samples being diluted 50-fold for accurate measurement. Standards and
test samples were assayed in duplicate. Both assays incorporate a specific murine
monoclonal antibody for each sTNF-R as a coating antibody, together with
horseradish peroxidase-conjugated polyclonal anti-sTNF-R antibodies. Accord-
ing to the manufacturers, these ELISA detect both free receptor and receptor
bound to TNF, as the assays are relatively insensitive to added TNF-α or TNF-
β (lymphotoxin α).
Statistical analysis Wilcoxon’s sign rank test (two-tailed) was used to
compare the values for the nonhealing and healing phases. The linear association
between pairs of assays was tested using Pearson’s correlation coefficient (r).
When the effect of healing status on the relationship between immunoreactive
and bioactive TNF-α was examined, regression analysis was performed using
the statistical software package S-PLUS version 3.2 (StatSci, Seattle, WA).
RESULTS
Patient data Wound fluid was collected from 21 patients with
chronic leg ulcers in both the nonhealing and the healing phases.
There were 13 male and eight female patients, with a median age of
78 y (range 31–91 y). In nine patients the ulcers were due to venous
disease alone, and another nine had combined venous and arterial
disease. Two patients with venous disease had noninsulin-dependent
diabetes, and one patient had venous and arterial disease and noninsulin-
dependent diabetes. These patients did not receive additional treatment
for the arterial component of their disease or any alteration in their
diabetic medications after admission to hospital.
The median initial size of the ulcers was 46 cm2 with an interquartile
range of 20–80 cm2. The median reduction in the size of the ulcers
after 2 wk bed rest was 8%, with an interquartile range of 2% to 23%.
Immunoreactive TNF-a are higher in the nonhealing
phase The levels of immunoreactive TNF-α in the wound fluid
samples were very high compared with normal plasma levels, with a
median of 1999.5 pg per ml and a range of 8.1 to 10970 pg per ml in
the Medgenix ELISA (normal plasma range 1–20 pg per ml, Medgenix
product information). The amount of TNF-α significantly decreased,
by µ70%, in the transition from the nonhealing phase to the healing
phase in both ELISA (Table I). The two ELISA assigned consistently
different absolute levels of TNF-α, despite the use of a common
reference standard, with the Medgenix assay assigning approximately
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Figure 1. Positive nonlinear association between values of TNF-a
detected by Medgenix EASIATM and Genzyme DuoseTTM ELISA in
40 wound fluid samples, but large differences in absolute values of
TNF-a assigned by each. The pattern of TNF-α content of the wound fluid
samples is similar within either ELISA, but values cannot be compared
between assays.
Table II. Levels of bioactive TNF-a in wound fluid from
nonhealing and healing ulcers (U per ml)
Nonhealing median Healing median
(interquartile range) (interquartile range) Significance level
156.1 (32.6–353.8) 49 (15.3–221.2) NSa
aNS, not significant.
3-fold more TNF-α than the Genzyme assay for the same sample
(Table I).
Figure 1 illustrates the strong association between the two sets of
ELISA results, and demonstrates that comparisons made between
samples are consistent within either assay, but that values cannot be
compared between assays.
Bioactive TNF-a are not significantly different between the
healing phases The bioassay results followed the same trend as the
ELISA results, but the difference between the nonhealing and healing
phases was not significant (Table II). The relationship between the
ELISA (Medgenix) and bioassay results was examined using simple
linear regression, and then by adding healing status as a factor in
multiple regression, fitting separate lines for the nonhealing and healing
groups. A significant linear correlation was found between the ELISA
and bioassay results (p , 0.001) with 71% (r2 5 0.71) of the observed
variation in bioactive TNF-α levels being explained by the ELISA
levels. There was a significant improvement in the amount of variation
explained when separate parallel lines were fitted for each healing
status (F1,34 5 7.6, p , 0.01), indicating that healing status is a factor
that significantly influences the relationship between ELISA and
bioactive TNF-α levels (Fig 2). Figure 2 demonstrates that for a
given amount of immunoreactive TNF-α, the bioactivity is lower in
wound fluid from nonhealing ulcers than in wound fluid from
healing ulcers.
Soluble p75 TNF receptor levels are higher in the nonhealing
phase There were significantly greater levels of soluble p75 receptors
in wound fluid from nonhealing ulcers than from healing ulcers, but
the levels of soluble p55 receptors remained at similar levels in both
healing phases (Table III). Like TNF-α levels, the levels of both types
of soluble receptors were much higher than those found in normal
plasma, with median values of 24423.5 pg per ml and 14044 pg per
ml, respectively, for the p75 and p55 soluble receptors (normal plasma
ranges; soluble p75, 1003–3170 pg per ml; soluble p55, 748.7–1966 pg
per ml). A significant linear association was shown between soluble
p75 and soluble p55 levels (r 5 0.78, p , 0.001) (Fig 3), but there
was no association between the levels of either soluble receptor and
immunoreactive or bioactive TNF-α levels (data not shown).
Figure 2. Relationship between ELISA and bioactive TNF-a is different
for nonhealing and healing wound fluid samples. When healing status is
included as a factor in regression analysis, two parallel lines representing the
nonhealing and healing samples explain the variation in the data significantly
better than a single line (F1,34 5 7.6, p , 0.01). The bioactivity of a given
amount of immunoreactive TNF-α was approximately 100 U per ml less in
wound fluid from nonhealing ulcers than in wound fluid from healing ulcers.
Figure 3. Significant linear correlation between soluble p75 and soluble
p55 TNF receptor levels in wound fluid samples. The relationship between
the two types of soluble TNF receptor measured by ELISA in 34 wound fluid
samples is shown. r 5 0.78; p , 0.025.
Table III. Levels of p75 and p55 soluble TNF receptors in
wound fluid from nonhealing and healing ulcers (pg per ml)
Nonhealing median Healing median Significance
(interquartile range) (interquartile range) level
Soluble p75 b26897 20616
(21433.2–31264.5) (15874.2–25929.2) p , 0.025
Soluble p55 14858.5 13930.5
(11693.5–17599) (8874–15396.8) NSa
aNS, not significant.
Molar ratio of soluble TNF receptor levels to immunoreactive
TNF-a is not high enough for substantial inhibition of TNF
bioactivity Molar ratios of sTNF-R levels to immunoreactive TNF-
α levels have been calculated by some authors to determine the excess
of soluble receptor required to inhibit the in vitro cytotoxicity of a
given amount of recombinant TNF-α (Loetscher et al, 1991; Van Zee
et al, 1992). These estimations can help predict whether levels of
sTNF-R measured in vivo are sufficient to block immunoreactive
TNF-α levels found in vivo. The cytotoxic effect of TNF-α on WEHI
164 clone 13 murine cells is reported to be inhibited by 50% in the
presence of a 30-fold molar excess of soluble p55 receptors, or a 300-
fold excess of soluble p75 receptors (Van Zee et al, 1992). If the molar
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ratios are determined for the data in this experiment using the same
calculations as Van Zee et al (assumed same molecular weight for all
molecules, not a true molar ratio), the range of ratios in the nonhealing
phase is 2.4–35.1 (median 12.4) for soluble p75/TNF-α, and 1.1–14.6
(median 6.5) for soluble p55/TNF-α (using the Medgenix TNF-α
data). Such calculations depend critically upon the absolute amount of
TNF-α detected by ELISA, so the ratios would be approximately 3-
fold higher if the Genzyme values were used.
DISCUSSION
In wound fluid samples from chronic venous ulcers at nonhealing and
healing phases, a significantly higher concentration of immunoreactive
TNF-α was detected in the nonhealing wound fluid samples by both
ELISA. The median amount of TNF-α in the nonhealing wound fluid
was extremely high (Medgenix, 2428 pg per ml). Whereas there was
a very strong positive association between the two TNF-α ELISA, the
quantitative differences in TNF-α concentrations between the assays
probably reflect differences in the epitopes detected by the antibodies
in the kits. The Medgenix ELISA may detect more forms of TNF-α
(e.g., proteolytically cleaved or complexed) than the Genzyme ELISA,
because it uses a cocktail of monoclonal coating antibodies rather than
a single monoclonal antibody. Such variation between commercial
TNF-α ELISA kits has been documented by Ledur et al (1995).
Despite the differences in the absolute values of TNF-α assigned, the
relative values between samples were consistent using either assay.
When we examined the correlation between immunoreactive TNF-
α and bioactive TNF-α we found a significant linear relationship.
Clinical studies have often demonstrated high levels of immunoreactive
TNF-α and sTNF-R coexisting with extremely low values of bioactive
TNF-α as measured by the murine L929 and WEHI 164 clone 13
assays (Jackson et al, 1995; Linderholm et al, 1996). The KYM-1D4
bioassay used here offers advantages over the murine cell lines, in that
it is a highly sensitive assay and species preference is eliminated (Meager,
1991). Using this assay we showed substantial levels of bioactive TNF-
α in both the nonhealing and healing phases.
In contrast to the levels of immunoreactive TNF-α decreasing
significantly with healing, the levels of bioactive TNF-α were not
significantly different between the nonhealing and healing phases,
although the median values did follow the same trend. When the
relationship between immunoreactive and bioactive TNF-α was exam-
ined, it was found that the observed variation in the data was
significantly better explained when healing status was assigned as a
separate factor. That is, the linear relationship between immunoreactiv-
ity and bioactivity was different for each phase of healing. The
bioactivity of immunoreactive TNF-α in wound fluid from nonhealing
ulcers was µ100 U per ml less than the bioactivity of the same amount
of immunoreactive TNF-α in wound fluid from healing ulcers. The
implication of this finding is that some variable associated with healing
status is able to modify the bioactivity of the TNF-α present in the
wound fluid.
The levels of the soluble p75 receptor were significantly elevated in
wound fluid from nonhealing ulcers compared with healing ulcers
(p , 0.025), and it is tempting to speculate that this was responsible
for modulating the activity of the TNF. Both types of sTNF-R have
been shown to be able to inhibit the cytotoxic activity of TNF-α
in vitro at high molar excesses of sTNF-R (Loetscher et al, 1991;
Higuchi and Aggarwal, 1992; Spinas et al, 1992; Van Zee et al, 1992;
Mohler et al, 1993), with Van Zee et al estimating that a 30-fold excess
of soluble p55, or a 300-fold excess of soluble p75, is required to
neutralize the cytotoxicity of 1500 pg recombinant human TNF-α
per ml. Because the median value of the molar excess of soluble p75/
immunoreactive TNF-α in nonhealing wound fluid was only 12.4,
and the median level of TNF-α in nonhealing wound fluid was
2428.5 pg per ml (Medgenix), it is unlikely that these levels of soluble
receptor were responsible for a substantial decrease in bioactivity. In
addition, there was no association between immunoreactive TNF-α
levels and the levels of either of the sTNF-R; however, calculations
such as molar ratios are difficult to compare between laboratories and
assays, and it cannot be ruled out that the combined effect of p55 and
p75 soluble receptors had some inhibitory activity.
At low values of the molar excess of sTNF-R, the effects of the
soluble receptors can augment the bioactivity of TNF-α in vitro by
stabilizing the structure of the trimeric TNF-α molecule (Aderka et al,
1992). These authors found that at the concentrations of TNF-α
present in these wound fluid samples, TNF-α deteriorates very
rapidly at 37°C (e.g., by 70% in 48 h) unless stabilized by sTNF-R.
Consequently, within the 48 h time-frame of the KYM-1D4 bioassay
it is possible that the measured cytotoxicity was a combination of the
free TNF-α present in the wound fluid at the beginning of the
incubation period, plus receptor-stabilized TNF-α that was released
during the incubation period. This confounding phenomenon may, in
part, explain the lack of an obvious relationship between bioactivity
and sTNF-R levels.
If the molar excess of soluble p75 receptors was not sufficient to
down-modulate the bioactivity of the TNF-α in nonhealing wound
fluid on its own, other factors may also be responsible. It has
been shown that neutrophil-derived proteolytic enzymes (cathepsin-
G, elastase) can inactivate TNF-α (Scuderi et al, 1991) and large
numbers of neutrophils are found in the dermis at the base and edge
of venous ulcers (Stacey et al, 1995) in which elastase activity has been
detected (Mirshahi et al, 1995).
In this study, the levels of the p55 and p75 soluble receptors showed
a strong linear correlation (p , 0.001), which is a feature of some,
but not all, in vivo scenarios. The same association has been found in
plasma of HIV-1-seropositive humans (Aukrust et al, 1994) and in a
sample of critically ill patients (Van Zee et al, 1992), but not in plasma
from humans with acute experimental endotoxinaemia (Spinas et al,
1992). Interestingly, the levels of neither soluble p55 nor soluble p75
receptors were correlated with immunoreactive TNF levels in our
wound fluid samples. In HIV-1-seropositive humans the plasma TNF-
α levels were associated with both soluble p55 and soluble p75 levels
(Aukrust et al, 1994), and in acute experimental endotoxinemia in
humans TNF-α levels were correlated with p75 but not p55 (Spinas
et al, 1992). Such differences may be induced by factors at the sites of
TNF-α production/activity, e.g., the proteolytic enzyme profile. It
appears that a common protease (or group of proteases) may be
responsible for some of the cleavage of the transmembrane TNF
receptors in this chronic venous ulcer environment, and that this is
not the same protease(s) involved in the cleavage of transmembrane
TNF-α. Collaborative work in our laboratory has shown that there
are elevated levels of matrix metalloproteinases in nonhealing versus
healing wound fluid.2 The major enzyme catalysing the release of
TNF-α from cells (TNF-α convertase) is believed to be a nonmatrix
metalloproteinase (Black et al, 1996).
Although a linear association was demonstrated between soluble p75
and p55 receptor levels, the significant decline in soluble p75 levels
but not p55 levels with healing suggests that additional regulatory
mechanisms for TNF receptor cleavage also exist. The cleavage
of membrane p75, but not p55, is reported to be dependent on
phosphorylation of the cytoplasmic domain (Brakebusch et al, 1992;
Crowe et al, 1993). In addition, the proteolytic enzymes present may
favor the cleavage of p75 over p55. Elastase from activated neutrophils
has been reported to mediate shedding of the p75 receptor but not
the p55 receptor (Porteu et al, 1991).
In conclusion, this study enhances our knowledge of the role of
TNF-α in the healing of chronic wounds, and also demonstrates that
local factors may influence the way that TNF activity is regulated.
Total TNF-α was significantly elevated in the nonhealing wound versus
the healing wound, but the accompanying bioactivity was not. Whereas
there is apparently a greater stimulus for TNF-α release in the
nonhealing phase, there appear to be other mechanisms operating that
can modulate TNF-α activity. The soluble TNF receptors do not
appear to play the sole role in limiting excessive TNF-α activity in
this chronic wound environment. The molar levels were low compared
with the levels of TNF-α present, and were not related to the amount
2Tarnuzzer R, Schultz G, Macauley S, Trengove N, Stacey M: Protease
levels in fluids collected from chronic venous/arterial leg ulcers before and
during healing. Wound Rep Reg 4:A142, 1996 (abstr.)
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of TNF-α present. Whether additional factors such as neutrophil
elastase or cathepsin-G were responsible for downregulating excessive
TNF-α activity can only be speculated from this study. This study
suggests that excessive TNF-α activity may not be the key factor in
the impaired healing of chronic venous ulcers, because healing was
initiated without a significant decline in the level of bioactive TNF-
α. Further work to examine the forms of TNF-α in wound fluid by
electrophoresis and immunoblotting, and to determine the levels of
key proteolytic enzymes, is necessary to assess the relative importance
of receptor binding and proteolytic cleavage in the regulation of TNF-
α bioactivity in the chronic wound environment.
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